MedTrace Logo

Efficacy, Safety of T2769 in Dry Eye Disease

NCT03830359 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-03-16

Study results available
· View outcomes & findings →

Summary

Efficacy of T2769 in Dry Eye Desease

Conditions

  • Dry Eye Syndrome

Interventions

OTHER

T2769

At least 55 enrolled patients for at least 50 evaluable patients treated by T2769 for 42 days

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-02-18
Completion
2019-02-18

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830359 on ClinicalTrials.gov